Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab B-cell depletion in early renal transplantation
ACTRN12610000420044Phase 4Withdrawn
- Sponsor
- Digestive Organ Transplantation Foundation
- Start
- Aug 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab in kidney allograft rejection and Chronic Allograft Kidney Disease (CKaD) (2 arms), sponsored by Digestive Organ Transplantation Foundation. Primary endpoints: Renal function estimated by Walser's equation, Renal pathology by BANFF criteria and 1 more. Planned start Aug 2008; status: withdrawn.
02
Drugs
rituximab
03
Conditions
kidney allograft rejectionChronic Allograft Kidney Disease (CKaD)
Beyond the preview
Go deeper on ACTRN12610000420044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000420044.